Tech Mahindra and NVIDIA collaborate to transform drug safety with AI

Tech Mahindra has announced a groundbreaking pharmacovigilance (PV) solution developed in collaboration with NVIDIA. This AI-powered solution leverages agentic artificial intelligence (AI) and automation to enhance drug safety management by improving the accuracy, speed, and efficiency of pharmacovigilance processes.

With pharmaceutical companies dealing with vast amounts of data during clinical trials and post-launch monitoring, the solution addresses key industry challenges such as manual delays and data overload. By integrating NVIDIA AI Enterprise software, including NVIDIA NeMo, NVIDIA NIM microservices, and NVIDIA AI Blueprints, Tech Mahindra’s PV solution streamlines case intake, data transformation, quality control, and compliance management. It also ensures regulatory adherence by automating processes and reducing human intervention.

How the AI-Powered Pharmacovigilance Solution Works

Tech Mahindra’s TENO framework, built on NVIDIA’s AI technology, forms the backbone of this solution. It employs large language model (LLM)-powered AI agents to autonomously handle case classification, prioritization, and verification of pharmacovigilance emails. This capability significantly reduces the risk of human error and enhances overall drug safety monitoring.

Pharmacovigilance teams handle over 1,000 daily cases of adverse drug reactions (ADR) for major pharmaceutical drugs. Traditional PV methods involve manual case processing, which is prone to delays and inefficiencies. With this AI-driven approach, when an ADR email is received, the solution instantly flags, prioritizes, and processes the case, minimizing the risk of oversight.

Key Benefits of the AI-Driven PV Solution

The AI-powered PV solution is designed to bring measurable improvements in drug safety management:

• 40% faster turnaround times for processing adverse drug reaction cases
• 30% improvement in data accuracy through AI-driven validation
• 25% reduction in operational costs by eliminating manual inefficiencies

This transition from a reactive to a predictive pharmacovigilance approach ensures timely case processing, improved regulatory compliance, and proactive risk mitigation, leading to better patient outcomes.

Expanding AI in Pharmacovigilance and Beyond

Tech Mahindra has further expanded its TENO framework to integrate NVIDIA AI Enterprise, enriching it with customized AI agents to address various industry challenges. By incorporating NVIDIA NeMo for generative AI pipeline acceleration and Tech Mahindra’s VerifAI solution for data validation and governance, the framework ensures continuous AI model improvements for enhanced decision-making precision.